prescription
Scope
Date
~
-
Bio & PharmaCostco sells Celltrion's Yuflyma Low WAC in US
South Korea's Celltrion Inc. announced on Tuesday that its autoimmune disease treatment Yuflyma (Low WAC, active ingredient adalimumab) is now avail...
Aug 13, 2024 (Gmt+09:00)
-
Bio & PharmaSK Biopharm targets $311 mn for Cenobamate US sales
South Korea's SK Biopharmaceuticals targeted 416 billion won ($311 million) for its epilepsy treatment Cenobamate in the US market this year. SK Bi...
Feb 16, 2024 (Gmt+09:00)
-
Bio & PharmaCelltrion applies for interchangeability of Yuflyma in US
South Korea's Celltrion Inc. announced on Wednesday that it has applied to the US Food and Drug Administration (FDA) for a modified approval to repl...
Jan 10, 2024 (Gmt+09:00)
-
Bio & PharmaCelltrion’s Vegzelma listed on prescription of 10 private US insurers
South Korea’s Celltrion Healthcare Co. announced on Wednesday that it has signed contracts with 10 insurance providers in the US to boost the ...
Aug 23, 2023 (Gmt+09:00)
-
Bio & PharmaCelltrion Healthcare enters top 10 in hospital prescriptions in Turkey
South Korean biopharmaceutical company Celltrion Healthcare Co. on Thursday said it ranked in the top 10 out of 400 companies last year on the Turki...
Apr 21, 2023 (Gmt+09:00)
-
Pre-IPOsLemon Healthcare aims for IPO and triple jump in revenue
Imagine making a doctor’s appointment with a click of a button on a smartphone app. Once at the clinic or hospital, the app will guide the use...
Jun 02, 2022 (Gmt+09:00)
Latest News
- 1 Korea’s top cinema chains seek merger to counter box office slump
- 2 S.Korea’s GEPS to commit $143 million to foreign mid-cap buyout funds
- 3 CJ CheilJedang to open $72 mn dumpling plant in Japan
- 4 LG Electronics breaks ground on $600 million home appliance plant in India
- 5 KakaoBank posts record Q1 profit, eyes Thai expansion after Indonesia
